Search

A recent preprint abstract discusses the structure and function of mouse α-synuclein fibrils, which are different from the human fibrils associated with Lewy body diseases. The study found that while mouse α-synuclein can fibrillize in vitro, the structures formed by these fibrils may not accurately reproduce those found in the human brain. The mouse fibrils displayed altered packing arrangements, reduced hydrophobicity, heightened fragmentation sensitivity, and weak immunological responses. Additionally, the mouse fibrils showed exacerbated pathological spread in neurons and humanized α-synuclein mice. These findings provide new insights into the role of mouse α-synuclein fibrils in the development of diagnostic probes and therapeutic interventions. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Vanderbilt University Medical Center explored the relationship between cerebrospinal fluid (CSF) motion and Parkinson's disease. The researchers used diffusion-weighted MRI to examine CSF motion in individuals with Parkinson's disease compared to healthy participants. The study found that CSF motion was reduced in individuals with Parkinson's disease, particularly in the posterior region of the suprasellar cistern. The findings suggest a potential link between CSF circulation disruptions and the retention of a-synuclein, a protein associated with Parkinson's disease. Further research is needed to fully understand the implications of these findings. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the impact of pathological α-synuclein (α-syn) on the basolateral amygdala (BLA) in Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). The study used mice injected with α-syn pre-formed fibrils (PFFs) to induce α-syn aggregate formation in the BLA. The results showed that α-synuclein caused significant alterations to synaptic architecture in the BLA, potentially contributing to behavioral impairment and amygdala dysfunction observed in synucleinopathies. However, there was no significant loss of synapses in the BLA due to α-syn aggregate formation. This research has not yet undergone peer review. [Extracted from the article]

A recent study published in Health & Medicine Week highlights the potential of targeting glial adenosine metabolism as a therapeutic approach for Parkinson's disease (PD). The researchers developed a Drosophila model to identify novel therapeutic targets for PD and found that knocking down certain genes involved in adenosine metabolism improved locomotor dysfunction, rescued neurodegeneration, and increased brain adenosine levels. Further investigation revealed that adenosine itself, rather than a downstream metabolite, played a role in neuroprotection. Metabolomics analysis in both Drosophila and human PD patients provided insights into changes in purine metabolism and potential biomarkers of dysfunctional adenosine metabolism. This research suggests that glial adenosine could be a promising therapeutic target for PD. [Extracted from the article]

A recent study conducted by the State Key Laboratory of Bioactive Substances and Functions of Natural Medicines has shed light on the early stages of Parkinson's disease (PD). The researchers found that the caudal raphe nuclei (CRN) in the brain are the initial site of gastric a-synuclein propagation, which is associated with PD. Over a period of 7 months, the locus coeruleus (LC) and substantia nigra pars compacta (SNpc) are subsequently affected. This study provides valuable insights into the "gut-brain" hypothesis and offers a potential PD model for future research on early intervention. [Extracted from the article]

A study conducted by researchers at Hirosaki University in Aomori, Japan, explores the neuropathology of Multiple System Atrophy (MSA), a degenerative disease. The study focuses on the presence of aggregated alpha-synuclein in the brain, specifically in glial cytoplasmic inclusions (GCIs). The researchers suggest that both oligodendrocytes and neurons may be primarily affected in MSA, and that impairment of autophagy may be implicated in the development of alpha-synucleinopathies. The findings highlight the potential role of vesicle-mediated transport and autophagy in the pathogenesis of MSA. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential regulation of the immune modulator tetraspanin CD81 by alpha-synuclein in melanoma. The study found that melanoma clones with low levels of CD81, a cell-surface protein that promotes invasion, migration, and immune suppression, were associated with high levels of alpha-synuclein. The researchers propose that high levels of alpha-synuclein may help melanoma cells evade the immune response. It is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

Researchers from the Children's Hospital of Philadelphia have published a new study on nerve tissue proteins, specifically focusing on alpha-synucleinopathy, a neurodegenerative disorder characterized by the accumulation of aggregated alpha-synuclein in brain cells. The study used positron emission tomography (PET) with a reactive oxygen species (ROS)-sensitive radiotracer to detect oxidative stress in a mouse model of synucleinopathy. The results showed that oxidative stress is an early and chronic process in the development of synucleinopathy, and PET imaging with the radiotracer holds promise for noninvasive detection of aSyn-associated oxidative stress. [Extracted from the article]

Renatus Inc., a South Korean company, has submitted a patent application for a method of treating proteinopathies, which are diseases characterized by abnormal protein aggregation and deposition. The method involves administering a pharmaceutical composition containing a gamma-cyclodextrin oligomer to individuals diagnosed with or at risk of developing proteinopathy. The composition aims to prevent or reduce protein aggregation, deposition, cytotoxicity, and inflammation associated with proteinopathies. Specific proteinopathies mentioned in the patent application include Alzheimer's disease, Parkinson's disease, and age-related macular degeneration. The average molecular weight of the gamma-cyclodextrin oligomer is between 2.5 kDa to 50 kDa. [Extracted from the article]

A recent report from Belmont University highlights the ongoing challenge of finding effective drugs or immunotherapeutic agents for the treatment and prevention of neurodegenerative diseases. The research emphasizes the need for creative approaches to identify biomarkers and develop disease-modifying strategies. The study focuses on the role of alpha-synuclein conformers in neuroinflammation and neuroimmune responses in Parkinson's disease. The authors discuss the potential for immunotherapeutic interventions and smart drug delivery systems to target these conformers and provide effective treatment options in the future. [Extracted from the article]

A recent study conducted by researchers at the University of Denver explores the use of protein mimetics as a potential therapeutic strategy for Parkinson's disease. The researchers developed a technique called 2D FAST (Fragment-Assisted Structure-based Technique) to identify antagonists of a-Synuclein aggregation, a process implicated in the development of Parkinson's disease. They identified a compound called NS132 that showed promise in inhibiting a-Synuclein aggregation and a more cell-permeable analog called NS163. These compounds were able to rescue Parkinson's disease phenotypes in early and post-disease models. The researchers believe that their technique has the potential to identify lead therapeutics for Parkinson's disease and other diseases. [Extracted from the article]

A new report from St. Petersburg State University in Russia provides insights into the role of the gut microbiome and bacterial amyloids in the development of synucleinopathies, including Parkinson's disease. The researchers collected data from over 130 experimental studies and found that there were several groups of bacteria that were overrepresented in patients with Parkinson's disease. The study suggests that changes in the gut microbiota may be associated with the development of synucleinopathies, and that bacterial proteins and metabolites may influence the aggregation of alpha-synuclein. This research has been peer-reviewed and provides up-to-date information on the topic. [Extracted from the article]

A recent study conducted by researchers at the University of Basel in Switzerland has shed light on the pathology of Multiple System Atrophy (MSA). MSA is characterized by the accumulation of alpha-synuclein (aSyn) in glial cytoplasmic inclusions (GCIs). The study utilized correlative light and electron microscopy to examine aSyn pathology in the brains of MSA patients. The researchers identified three distinct types of aSyn inclusions in oligodendrocytes, neurons, and dark cells. The findings suggest a complex interplay between different cell types in the formation of aSyn pathology in MSA and highlight the need for further investigation into cell-specific disease pathologies. [Extracted from the article]

Researchers at the University of Paris Saclay have released new data on Parkinson's Disease. The study focuses on the potential use of doxycycline, an antibiotic, for the treatment of Parkinson's Disease. While doxycycline has limitations due to its antibiotic activity, the researchers designed and synthesized modified derivatives of doxycycline that showed improved inhibition of alpha-synuclein aggregation and anti-inflammatory effects. These findings suggest that these newly designed tetracyclines could be promising drug candidates for the treatment of Parkinson's Disease. Further in-vivo studies are needed to confirm these results. [Extracted from the article]

A recent study investigated the effects of overexpressing the protein alpha-synuclein in dopamine neurons in the substantia nigra region of the brain. Alpha-synuclein is associated with Parkinson's disease, but its role in the selective vulnerability of dopamine neurons is not well understood. The study found that increasing alpha-synuclein levels did not lead to neurodegeneration in these neurons, but it did result in increased dopamine activity and locomotor activity. These findings suggest that elevated alpha-synuclein alone is not enough to trigger acute dopamine neurodegeneration. [Extracted from the article]

The patent application titled "Personalized Medicine Approach For Treating Cognitive Loss" discusses a method for treating cognitive decline or dysfunction by measuring the expression level of proinflammatory biomarkers in a blood sample and administering an NSAID such as naproxen or celecoxib. The application also describes a method for determining the effectiveness of an NSAID clinical trial by measuring biomarker expression levels before and after drug administration. The patent application references previous patents and applications related to diagnosing and treating neurodegenerative diseases and autism spectrum disorders. This method aims to treat cognitive decline by identifying biomarker expression levels and administering appropriate medication. [Extracted from the article]

Researchers from the Universitat Autonoma de Barcelona have identified a region in the early aggregates of the alpha-synuclein protein that can be targeted to prevent its conversion into toxic amyloid fibrils, which accumulate in the brains of people with Parkinson's disease. This discovery could lead to the development of new therapeutic strategies for inactivating these aggregates. The researchers also found that a specific mutation in this critical region is associated with familial Parkinson's disease, and they are working on developing personalized therapies for individuals with this mutation. The study involved collaboration with researchers from other universities and institutions. [Extracted from the article]

A new report from Chang Gung University in Taiwan discusses the association between Gaucher's disease and Parkinson's disease (PD). The study found that individuals with the GBA L444P mutation had a significantly increased risk of PD. The researchers also examined the protective effects of Coptis chinensis rhizome extract and its constituents (berberine, coptisine, and palmatine) against PD. The extract and its constituents were found to reduce alpha-synuclein aggregation, enhance GBA expression and autophagy, and protect against alpha-synuclein neurotoxicity. These findings suggest the therapeutic potential of Coptis chinensis rhizome extract and its constituents for PD. [Extracted from the article]

A recent study published in Pain & Central Nervous System Week explores the potential use of lysosome-acidifying nanoparticles as a therapeutic approach for Parkinson's disease (PD). PD is a neurodegenerative disease characterized by the accumulation of alpha-synuclein (Syn) and the loss of dopaminergic neurons. The study found that these nanoparticles can restore lysosomal acidification, promote autophagic clearance of Syn, improve mitochondrial function, and rescue neuronal death in cellular and Drosophila models of PD. This research suggests that lysosome-acidifying nanoparticles could be a promising treatment for PD and other proteinopathies. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent preprint abstract discusses the development of a potential therapeutic candidate for synucleinopathies, a group of neurodegenerative diseases characterized by the accumulation of a protein called alpha-synuclein in the brain. The researchers developed a single-domain antibody-based protein degrader that targets alpha-synuclein and a protein called Cereblon, which promotes its degradation. The study found that this therapeutic candidate enhanced the clearance of alpha-synuclein in cell cultures and mouse models of synucleinopathy. The researchers suggest that this approach shows promise for the treatment of synucleinopathies, although further research is needed. [Extracted from the article]

Researchers at the Institute of Nano Science and Technology in Punjab, India have conducted a study on the therapeutic efficacy of Hytrin Therapy in reducing nitrated synucleinopathy, a major cause of Parkinson's disease (PD) progression. The study utilized hytrin-loaded polydopamine-serotonin nanoparticles to improve the therapeutic efficacy of hytrin. The nanoformulation showed neuroprotective efficiency and activated chaperone-mediated autophagy to reduce nitrated synuclein. This research provides insights into potential treatments for PD. [Extracted from the article]

A recent study from Michigan State University examined the impact of colony stimulating factor-1 receptor (CSF1R) inhibition on the microglial response to alpha-synuclein (a-syn) inclusions in Parkinson's disease (PD). The researchers found that CSF1R inhibition did not affect the microglial response or the accumulation of a-syn inclusions. Additionally, CSF1R inhibition did not alter the degeneration of nigral neurons. These findings suggest that CSF1R inhibition is not a viable strategy for modifying the progression of PD. [Extracted from the article]

Researchers at the First Affiliated Hospital of Zhengzhou University in China have conducted a study on the characteristics of cutaneous synucleinopathy in genetic Parkinson's disease (PD) patients. The study aimed to detect the deposition of phosphorylated alpha-synuclein (p-a-syn) in the skin of PD patients with specific genetic mutations. The researchers found that p-a-syn was deposited in the peripheral cutaneous nerves of PD patients with CHCHD2, LRRK2, or GBA mutations, but not in those with RAB39B or PRKN mutations. The study suggests that cutaneous synucleinopathy may serve as a biomarker for genetic PD and idiopathic PD in the future. [Extracted from the article]

A new report from the Institut des Maladies Neurodegeneratives discusses research findings on nerve tissue proteins. The study focuses on the viral vector-mediated delivery of a-synuclein, a protein associated with neurodegenerative diseases. The researchers developed a bioluminescent expression reporter to monitor the expression of the A53T-a-synuclein gene in mice. They found that the addition of fibroin, a protein, increased the intensity and magnitude of the cerebral bioluminescence signal. However, they also observed a bioluminescence signal in peripheral organs. This research provides insights into the diffusion and expression of a-synuclein in the central nervous system and peripheral tissues. [Extracted from the article]

A study conducted by researchers at Fujian Medical University in Fuzhou, China, explored the structural alterations in white matter (WM) in patients with alpha-synucleinopathies experiencing orthostatic hypotension (OH). The study used axial diffusivity and density imaging (NODDI) to investigate WM damage and found distinctive patterns of microstructural damage in the WM of patients with alpha-synucleinopathies experiencing OH. These patterns were correlated with the onset and progression of non-motor functional impairments. The findings contribute to a better understanding of the pathogenic mechanisms and pathological rationales behind the occurrence of non-motor symptoms in alpha-synucleinopathies. [Extracted from the article]

Researchers from the Medical College of Wisconsin have published a report exploring the role of short-chain fatty acids (SCFAs) produced by the gut microbiome in Parkinson's disease (PD). SCFAs, such as acetate, propionate, and butyrate, are involved in gut-brain communication and can modulate alpha-synuclein aggregation, a hallmark of PD. The gut microbiome of PD patients has lower levels of SCFAs compared to healthy individuals. The researchers suggest that probiotics may be a potential strategy to restore SCFAs and alleviate PD symptoms. They also discuss how alpha-synuclein, found in the guts and brains of PD patients, may induce neuroinflammation and oxidative stress. Understanding the role of SCFAs in the gut microbiome and their impact on alpha-synuclein-induced neuroinflammation and oxidative stress is crucial for PD treatment. [Extracted from the article]

A recent study conducted at the University of Alberta in Canada has explored the development of vaccines targeting misfolded alpha-synuclein conformers, which are associated with neurodegenerative disorders such as Parkinson's disease. The researchers used a rational design approach, incorporating specific amino acid substitutions onto a scaffold protein to mimic the structure of alpha-synuclein fibrils. The vaccine candidates successfully induced the production of antibodies that recognized pathological alpha-synuclein aggregates in mouse models and brain lysates from patients with related disorders. This research provides a promising avenue for the development of effective vaccines against alpha-synuclein fibrils. [Extracted from the article]

A recent study conducted by researchers at the University of Toronto has identified a rare variant of multiple system atrophy, a neurodegenerative disease. The study found that in some cases, there is an overlap between amyloid-beta and alpha-synuclein protein depositions in the brain, specifically in the striatum or cerebellum. The presence of amyloid-beta in these regions may have implications for the effectiveness of alpha-synuclein-targeted therapies. The researchers suggest that mixed pathologies should be considered not only based on clinical differences but also on regional protein overlap. [Extracted from the article]

A recent study conducted at Mansoura University in Egypt explored the potential role of stinging nettle (Urtica dioica L.) in the management of Parkinson's disease. The researchers found that nettle supplementation in rats with rotenone-induced Parkinson's disease led to the recovery of dopaminergic neurons in the midbrain. Nettle was found to inhibit apoptosis, inflammation, and oxidative stress, as well as restore the autophagic machinery and clear alpha-synuclein deposits. The study suggests that nettle could be a potentially effective adjuvant in the treatment of Parkinson's disease. [Extracted from the article]

A recent report from the National Institute on Aging discusses the potential of immunotherapy in treating neuroinflammation in synucleinopathies such as Parkinson's disease and dementia with Lewy bodies. The researchers treated transgenic mice with an antibody against CD1d, a glycoprotein expressed in antigen presenting cells. The treatment reduced neuroinflammation and neurodegenerative pathology in the mice, suggesting that targeting NKT cells with an anti-CD1d antibody could be a potential therapeutic approach for these diseases. Further research is needed to explore the efficacy of this treatment in humans. [Extracted from the article]

A recent study conducted by the Department of Applied Research has found that plasminogen, a major extracellular proteolysis system, plays a crucial role in Parkinson's disease (PD). The study showed that plasminogen crossed the blood-brain barrier, entered cells, and migrated to the nucleus, where it increased plasmin activity and promoted the clearance of a-synuclein, Tau, and TDP-43 proteins. This resulted in a decrease in dopaminergic neurodegeneration and an improvement in motor function in mouse models of PD. These findings suggest that plasminogen may be a promising candidate for PD treatment. [Extracted from the article]

A recent study conducted by researchers at the University of Porto has found that the accumulation of alpha-synuclein (aSyn) in the hippocampus, a region of the brain, is linked to cognitive deficits in Lewy Body dementias (LBD). The study discovered that aSyn triggers the formation of cofilin-actin rods, which disrupt synapses and impair cognitive function. The researchers also identified the cellular prion protein (PrPC) and the chemokine receptor 5 (CCR5) as key factors in this process. Importantly, the study suggests that inhibiting CCR5 could potentially prevent synaptic impairment and cognitive dysfunction in LBD. [Extracted from the article]

A recent report discusses research on nerve tissue proteins and their association with Parkinson's disease. The study focuses on synucleins, which are proteins that can modulate various pre-synaptic processes in the brain. The researchers analyzed the electroencephalogram (EEG) coherence between different brain structures in mice lacking alpha, beta, and gamma synucleins. They found that the deletions of these synucleins led to a significant attenuation of intra-cerebral EEG coherence, depending on the imbalance of different types of synucleins. This research provides insights into the role of synucleins in neurodegenerative diseases. [Extracted from the article]

A recent report from the University of Jinan in Guangzhou, China discusses the findings of a study on nerve tissue proteins. The study focuses on the aggregation of alpha-synuclein (alpha-syn) and its role in Parkinson's disease. The researchers found that tetramethylpyrazine nitrone (TBN) promotes the clearance of alpha-syn through the ubiquitin-proteasome system (UPS) by activating the nuclear factor (erythroid-derived 2)-like 2 (Nrf2). TBN was also found to improve motor impairment and decrease oxidative damage in a mouse model of Parkinson's disease. The study suggests that TBN could be a potential therapeutic agent for Parkinson's disease. [Extracted from the article]